论文部分内容阅读
支气管哮喘患者35例,男23例,女12例,年龄13～36岁。所有患者均吸入二丙酸倍氯米松(BDP)600μg/d达6个月,并按1993年制订的哮喘疗效判定标准达到临床控制。然后停用BDP随诊3个月,并分别于起始、1个月及3个月后测定肺功能(chesta-65肺功能仪),选用FVC、FEV_(1.0)、PF及V_(50)四项指标。随诊期间如有急性发作则按需要给予氨茶碱,舒喘灵或强的松。数据处理采用配对t检验。1 结果 停用BDP后3个月内共有16例患者出现急性发作,占45.7％。停用BDP1个月后FVC、PF、
35 cases of bronchial asthma patients, 23 males and 12 females, aged 13 to 36 years old. All patients received 600 mg / day of beclomethasone dipropionate (BDP) for 6 months and achieved clinical control according to the criteria of asthma efficacy established in 1993. Then BDP was discontinued for 3 months, and lung function (chesta-65 pulmonary function test) was measured at the beginning, 1 month and 3 months after operation. FVC, FEV 1.0, PF and V 50, Four indicators. Acute episodes during follow-up if necessary, given aminophylline, salbutamol or prednisone. Data processing paired t-test. 1 Results In the 3 months after the discontinuation of BDP, a total of 16 patients developed acute attacks, accounting for 45.7%. Disable BDP 1 month after FVC, PF,